闵瑞,刘洁,代喆,孙家忠,邓浩华,李新,吴玉文,黄芪,孙力,杨杪,徐焱成

• 1:武汉大学中南医院内分泌科

摘要(Abstract)：

新型冠状病毒肺炎(Corona virus disease 2019,COVID-19)是由一种新的β冠状病毒-新型冠状病毒(2019 novel coronavirus,2019-nCoV)引起,以血管紧张素转化酶2(Angiotensin converting enzyme 2,ACE2)作为受体侵入细胞导致肺损伤,病情加重与继发引起的全身性炎症反应密切相关,重症患者会出现急性呼吸窘迫综合征(Acute respiratory distress syndrome,ARDS)和感染性休克,最终出现多器官功能衰竭。目前大多数药物如巴利替尼、瑞德西韦、氯喹等尚处于临床试验阶段,尚无特效药治疗。COVID-19传染性强,可引起多种严重的并发症,对全球公共安全造成了极大威胁。研究其病原学及发病机制,进而开展对治疗药物和疫苗的临床研究,对及时控制病毒传播,防止病情恶化进展,减少并发症及病死率具有重大意义。

关键词(KeyWords)： 新型冠状病毒肺炎;新型冠状病毒;冠状病毒

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 闵瑞,刘洁,代喆,孙家忠,邓浩华,李新,吴玉文,黄芪,孙力,杨杪,徐焱成

参考文献(References)：

• [1] Lu H,Stratton CW,Tang YW.Outbreak of pneumonia of unknown etiology in Wuhan,China:The mystery and the miracle[J].J Med Virol,2020,92(4):401-402.
• [2] Hui DS,I Azhar E,Madani TA,et al.The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan,China[J].Int J Infect Dis,2020,91:264-266.
• [3] World Health Organization.Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected:interim guidance[EB/OL].(2020-02-26).https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
• [4] 新华网.截至2月25日24时新型冠状病毒肺炎疫情最新情况[EB/OL].(2020-02-26).http://www.xinhuanet.com/politics/2020-02/26/c_1125626972.htm.
• [5] Fung TS,Liu DX.Human coronavirus:host-pathogen interaction[J].Annu Rev Microbiol,2019,73:529-557.
• [6] Chan JF,To KK,Tse H,et al.Interspecies transmission and emergence of novel viruses:lessons from bats and birds[J].Trends Microbiol,2013,21(10):544-555.
• [7] Richard A Kock,William B Karesh,Francisco Veas,et al.2019-nCoV in context:lessons learned?[J].Published Online February 6,2020 https://doi.org/10.1016/S2542-5196(20)30035-8.
• [8] Cheng VC,Lau SK,Woo PC,et al.Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection[J].Clin Microbiol Rev,2007,20(4):660-694.
• [9] Singh SK.Middle East Respiratory Syndrome Virus Pathogenesis[J].Semin Respir Crit Care Med,2016,37(4):572-577.
• [10] Huang C,Wang Y,Li X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
• [11] Lu R,Zhao X,Li J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
• [12] World Health Organization.Novel coronavirus-China.Geneva,Switzerland:World Health Organization,January12,2020[EB/OL].(2020-02-26).https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
• [13] GenBank.Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1,complete genome[EB/OL].(2020-02-26).https://www.ncbi.nlm.nih.gov/nuccore/MN908947.
• [14] Zhou P,Yang XL,Wang XG,et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020:1-4.
• [15] Fan Wu,Su Zhao,Bin Yu,et al.A new coronavirus associated with human respiratory disease in China[J].Nature(2020):1-8.
• [16] Tommy Tsan-Yuk Lam,Marcus Ho-Hin Shum,Hua-chen Zhu,et al.Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China[J].bioRxiv,2020.doi:https//doi:org/10.1101/2020.02.13.945485.
• [17] Van Regenmortel MHV,Fauquet CM,Bishop DHL,et al.Virus taxonomy:classification and nomenclature of viruses seventh report of the International Committee on Taxonomy of Viruses[M].San Diego:Academic Press,2000,835-849.
• [18] Su S,Wong G,Shi W,et al.Epidemiology,genetic recombination,and pathogenesis of coronaviruses[J].Trends Microbiol,2016,24(6):490-502.
• [19] Siu YL,Teoh KT,Lo J,et al.The M,E,and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly,trafficking,and release of virus-like particles[J].J Virol,2008,82(22):11318-11330.
• [20] Venkatagopalan P,Daskalova SM,Lopez LA,et al.Coronavirus envelope (E) protein remains at the site of assembly[J].Virology,2015,478:75-85.
• [21] Neuman BW,Kiss G,Kunding AH,et al.A structural analysis of M protein in coronavirus assembly and morphology[J].Struct Biol,2011,174(1):11-22.
• [22] de Haan CA,Rottier PJ.Molecular interactions in the assembly of coronaviruses[J].Adv Virus Res,2005,64:165-230.
• [23] Wu A,Peng Y,Huang B,et al.Genome composition and divergence of the novel coronavirus(2019-nCoV) originating in China[J].Cell Host Microbe,2020.
• [24] de Wit E,van Doremalen N,Falzarano D,et al.SARS and MERS:recent insights into emerging coronaviruses[J].Nat Rev Microbiol,2016,14(8):523-534.
• [25] Li W,Moore MJ,Vasilieva N,et al.Angiotensin- converting enzyme 2 is a functional receptor for the SARS coronavirus[J].Nature,2003,426:450-454.
• [26] Qian Z,Travanty EA,Oko L,et al.Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome- coronavirus[J].Am J Respir Cell Mol Biol,2013,48:742-748.
• [27] Lu G,Hu Y,Wang Q,et al.Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26[J].Nature,2013,500(7461):227-231.
• [28] Scobey T,Yount BL,Sims AC,et al.Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus[J].Proc Natl Acad Sci U S A,2013,110(40):16157-16162.
• [29] Wan Y,Shang J,Graham R,et al.Receptor recognition by novel coronavirus from Wuhan:An analysis based on decade-long structural studies of SARS[J].J Virol,2020.
• [30] Wrapp D,Wang N,Corbett KS,et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J].Science,2020.
• [31] Zhou Q,Yan RH,Zhang YY,et al.Structure of dimeric full-length human ACE2 in complex with B0AT1[J].bioRxiv,2020.
• [32] Morse JS,Lalonde T,Xu S,et al.Learning from the past:possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV[J].Chembiochem,2020-01-27T13:11:15Z(GMT).
• [33] Kuba K,Imai Y,Rao S,et al.A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J].Nat Med,2005,11(8):875-879.
• [34] Imai Y,Kuba K,Rao S,et al.Angiotensin-converting enzyme 2 protects from severe acute lung failure[J].Nature,2005,436:112-116.
• [35] Richardson P,Griffin I,Tucker C,et al.Baricitinib as potential treatment for 2019-nCoV acute respiratory disease[J].Lancet,2020,395(10223):e30-e31.
• [36] Liu Y,Yang Y,Zhang C,et al.Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[J].Sci China Life Sci,2020.
• [37] Jimenez-Guardeno JM,Nieto-Torres JL,DeDiego ML,et al.The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis[J].PLoS Pathog,2014,10(8):e1004320.
• [38] Liang C,Xiangjie L,Mingquan C,et al.The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2[J].Cardiovascular Research.https://doi.org/10.1093/cvr/cvaa078.
• [39] Zhang H,Kang ZJ,Gong HY,et al.The digestive system is a potential route of 2019-nCov infection:a bioinformatics analysis based on single-cell transcriptomes[J].bioRxiv,2020.
• [40] Chen XX,Fu Y,Lei C,et al.Caution on kidney dysfunctions of 2019-nCoV patients[J].bioRxiv,2020.DOI:https://doi.org/10.1101/2020.02.08.20021212.
• [41] Hui DSC,Zumla A.Severe acute respiratory syndrome historical,epidemiologic,and clinical features[J].Infect Dis Clin N Am,2019,33(4):869-889.
• [42] Chen N,Zhou M,Dong X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507-513.
• [43] Wang DW,Hu B,Hu C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia inWuhan,China[J].JAMA,2020.doi:10.1001/jama.2020.1585.
• [44] Wang FS,Zhang C.What to do next to control the 2019-nCoV epidemic?[J].LANCET,2020,395(10222):391-393.
• [45] Shimabukuro-Vornhagen A,Godel P,Subklewe M,et al.Cytokine release syndrome Immunother Cancer[J].2018,6(1):56.
• [46] Liu J,Zheng X,Tong Q,et al.Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV,MERS-CoV,and 2019-nCoV[J].J Med Virol,2020.ORCID iD:0000-0002-8262-4997.
• [47] Xu Z,Shi L,Wang Y,et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].Lancet Respir Med,2020.DOI:https://doi.org/10.1016/S2213-2600(20)30076-X.
• [48] 中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志,2020,41(2):145-151.
• [49] Yang Y,Lu QB,Liu MJ,et al.Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China[J].MedRxiv,2020.doi:https://doi.org/10.1101/2020.02.10.20021675.
• [50] Yin Y,Wunderink RG.MERS,SARS and other corona viruses as causes of pneumonia[J].Respirology,2018,23:130-137.
• [51] Song Z,Xu Y,Bao L,et al.From SARS to MERS,thrusting corona viruses into the spotlight[J].Viruses,2019,11:59.
• [52] Chu DKW,Pan Y,Cheng SMS,et al.Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia[J].Clin Chem,2020.
• [53] Dennis Lo YM,Chiu RWK.Racing towards the development of diagnostics for a novel coronavirus (2019-nCoV)[J].Clin Chem,2020.DOI:10.1093/clinchem/hvaa038.
• [54] PanY,GuanH,ZhouS,et al.Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV):a study of 63 patients in Wuhan,China[J].EurRadiol,2020.DOI:10.1007/s00330-020-06731-x.
• [55] Chung M,Bernheim A,Mei X,et al.CT imaging features of 2019 novel coronavirus (2019-nCoV)[J].Radiology,2020:200230.
• [56] Pan F,Ye TH,Sun P,et al.Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia[J].Radiology,2020.
• [57] PanY,GuanH.Imaging changes in patients with 2019-nCov[J].Eur Radiol,2020.https://doi.org/10.1007/s00330-020-06713-z.
• [58] Xie XZ,Zhong Z,Zhao W,et al.Chest CT for typical 2019-nCoV pneumonia:relationship to negative RT-PCR testing[J].Radiology,2020.
• [59] Song FX,Shi NN,Shan F,et al.Emerging coronavirus 2019-nCoV pneumonia[J].Radiology,2020.
• [60] Li GD,Erik De Clercq.Therapeutic options for the 2019 novel coronavirus (2019-nCoV)[J].Nature Rev Drug Discov,2020.DOI:10.1038/d41573-020-00016-0.
• [61] Vincent MJ,Bergeron E,Benjannet S,et al.Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J].Virology Journal,2005,2(1):69.
• [62] Kono M,Tatsumi K,Imai AM,et al.Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine:involvement of p38 MAPK and ERK[J].Antiviral Res,2008,77(2):150-152.
• [63] Richardson P,Griffin I,Tucker C,et al.Baricitinib as potential treatment for 2019-nCoV acute respiratory disease[J].Lancet,2020,395(10223):e30-e31.
• [64] Wang M,Cao R,Zhang L,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J].Cell Research,2020.
• [65] Lu H.Drug treatment options for the 2019-new coronavirus(2019-nCoV)[J].Biosci Trends,2020.doi:10.5582/bst.2020.01020.
• [66] World Health Organization.Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected[EB/OL].(2020-01-28).https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
• [67] Russell CD,Millar JE,Baillie JK.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J].Lancet,2020,395(10223):473-475.
• [68] 湘雅医院重症医学科.湖南省重型、危重型新型冠状病毒感染的肺炎治疗方案(试行第一版)[EB/OL].(2020-02-19)[2020-02-26].https://www.xiangya.com.cn/english/Content.aspx?chn=284&id=47206.
• [69] Zumla A,Hui DS,Azhar EI,et al.Reducing mortality from 2019-nCoV:host-directed therapies should be an option[J].Lancet,2020,395(10224):e35-e36.
• [70] Chen Y,Liu Q,Guo D.Emerging coronaviruses:genome structure,replication,and pathogenesis[J].J Med Virol,2020,92(4):418-423.